 |
|
|
|
 |
|
|
| Article 1 to 10 out of 14 concerning Clavis Pharma ASA
|
-
Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer
(12 Jan 2010)
Clavis Pharma announced that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European Commission in ...
-
Clavis Pharma appoints Olav Hellebų as Chief Executive Officer
(12 Jan 2010)
Clavis Pharma ASA announced that it has appointed Olav Hellebų as its new Chief Executive Officer (CEO). Mr Hellebų, who joins Clavis Pharma from UCB Pharma, has significant senior management experience in the pharmaceutical industry and has been ...
-
Clavis Pharma and Clovis Oncology Sign Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126
(25 Nov 2009)
Clavis Pharma to receive up to $380 million in staged payments, including a $15 million signing fee, and tiered double-digit royalties on sales
Clavis Pharma ASA and Clovis Oncology, Inc. announced an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer. CP-4126 is a patented, ...
-
The European Commission grants Orphan Drug Designation for Intravenous CP-4126 for the Treatment of Pancreatic Cancer
(03 Nov 2009)
Clavis Pharma ASA announced that the European Commission has granted Orphan Drug Designation (Orphan Medicinal Product) for Intravenous CP-4126 for the treatment of pancreatic cancer. The designation follows the recommendation given by the European ...
-
The European Medicines Agency recommends Orphan Drug Designation of Intravenous CP-4126 for the Treatment of Pancreatic Cancer
(15 Sep 2009)
Clavis Pharma announced that the European Medicines Agency (EMEA) has recommended orphan drug designation to Intravenous CP-4126 for the treatment of pancreatic cancer. Clavis Pharma is currently conducting a Phase II study with Intravenous CP-4126 ...
-
Clavis Pharma receives USD 1.1 million Grant to Accelerate the Phase II Programme of Intravenous CP-4126 in Pancreatic Cancer
(28 Aug 2009)
Clavis Pharma ASA announced that it has received a government grant of up to USD 1.1 mill (NOK 6.9 mill) to accelerate the Phase II clinical programme with Intravenous CP-4126 in patients with newly diagnosed, advanced pancreatic cancer. The grant ...
-
Clavis Pharma announces successful Investigational New Drug application (IND) review for Intravenous CP-4126
(06 Jul 2009)
Clavis Pharma ASA announces that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Intravenous CP-4126. Intravenous CP-4126 is in development as a ...
-
Clavis Pharma raises USD 20 million in a private placement to fund further development of its anticancer drug pipeline
(29 Jun 2009)
Clavis Pharma ASA announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share.The ...
-
Clavis Pharma: Phase II trial demonstrates Elacytarabine may increase survival threefold in patients with late-stage leukaemia
(18 Jun 2009)
Clavis Pharma ASA announced positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically ...
-
Clavis Pharma Announces Positive Elacytarabine Phase II Results
(19 Mar 2009)
Independent data monitoring committee confirms initial results
Clavis Pharma ASA announced positive results from a second interim analysis of the elacytarabine (CP-4055). Phase II study in patients with late stage acute myeloid leukaemia (AML). An interim analysis of data from 40 patients has been assessed by ...
Additional information
Clavis Pharma ASA
Oslo, Norway
Company
|
|
|
|
|
|
Top
